417 completed. 417 Phase 2, 44 Phase 3, 41 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 417 | Completed 417 |
| Phase 3 | 44 | Completed 44 |
| Phase 1 | 41 | Completed 41 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients Ropanicant, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Completed | Suven Life Sciences Limited | 214 | 2025-07-15 | 2026-04-07 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray - Major Depressive Disorder (MDD | Phase 2 | Completed | Sichuan Purity Pharmaceutical Technology Co., Ltd. | 98 | 2025-05-27 | 2026-09-09 |
| A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder KH607 tablets, placebo - Major Depressive Disorder (MDD) | Phase 2 | Completed | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 126 | 2025-03-19 | 2026-07-28 |
| A Study of ONO-1110 in Patients With Major Depressive Disorder ONO-1110, Placebo - Major Depressive Disorder (MDD | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 103 | 2025-01-16 | 2026-07-08 |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) VLS-01-203 BU, VLS-01-BU Placebo - Treatment Resistant Depression | Phase 2 | Completed | atai Therapeutics, Inc. | 142 | 2024-12-30 | 2026-10-30 |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder JNJ-89495120, Placebo - Depressive Disorder, Major | Phase 2 | Completed | Janssen Research & Development, LLC | 105 | 2024-12-26 | 2026-09-25 |
| A Phase II Study to Evaluate NH102 for Depression NH102, Duloxetine Hydrochloride Enteric-coated Capsule, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Completed | Jiangsu Nhwa Pharmaceutical Co., Ltd. | 243 | 2024-12-04 | 2026-09-22 |
| Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers Psilocybin, Cognitive Behavioral Therapy (CBT) - Major Depressive Disorder | Phase 2 | Completed | Khyber Medical University Peshawar | 60 | 2024-12-01 | 2025-09-02 |
| A Study to Test Different Doses of BI 1569912 in People With Depression 5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912 - Depressive Disorder, Major | Phase 2 | Completed | Boehringer Ingelheim | 225 | 2024-10-01 | 2026-05-22 |
| Efficacy of MI078 Capsules in Treating Postpartum Depression MI078 capsule dose 1, MI078 capsule dose 2, placebo - Postpartum Depression | Phase 2 | Completed | Nanjing Minova Pharmaceutical Co., Ltd. | 72 | 2024-09-09 | 2026-06-25 |
| Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) BHV-7000 - Major Depressive Disorder | Phase 2 | Completed | Biohaven Therapeutics Ltd. | 233 | 2024-08-01 | 2026-10-14 |
| Psilocybin for Treatment-Resistant Depression Psilocybin 25mg, Placebo (active placebo) - Major Depressive Disorder, Anhedonia | Phase 2 | Completed | University of Colorado, Denver | 20 | 2024-07-08 | 2026-05-22 |
| RE104 Safety and Efficacy Study in Postpartum Depression RE104 for Injection - Postpartum Depression | Phase 2 | Completed | Reunion Neuroscience Inc | 84 | 2024-06-14 | 2026-05-14 |
| Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression BHV-7000, Placebo - Major Depressive Disorder | Phase 2 | Completed | Biohaven Therapeutics Ltd. | 336 | 2024-05-28 | 2026-10-14 |
| Trial of Mirtazapine for Depression in IBD Mirtazapine, Placebo - Major Depressive Disorder, Inflammatory Bowel Diseases | Phase 2 | Completed | King's College London | 76 | 2024-05-07 | 2026-08-19 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression NORA520 Dose 1, NORA520 Dose 2, Placebo - Depression, Postpartum, Postpartum Depression | Phase 2 | Completed | TWi Biotechnology, Inc. | 93 | 2024-03-28 | 2026-07-31 |
| A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine BI 1569912, Placebo - Depressive Disorder, Major | Phase 2 | Completed | Boehringer Ingelheim | 243 | 2024-03-27 | 2026-03-27 |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder SP-624, Placebo - Major Depressive Disorder | Phase 2 | Completed | Sirtsei Pharmaceuticals, Inc. | 497 | 2024-03-25 | 2026-08-18 |
| PD, PK, and Safety of ALTO-203 in Patients With MDD ALTO-203 25 μg, ALTO-203 75 μg, Placebo - Major Depressive Disorder, Anhedonia | Phase 2 | Completed | Alto Neuroscience | 69 | 2024-03-25 | 2026-04-17 |
| A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder NBI-1070770, Placebo - Major Depressive Disorder | Phase 2 | Completed | Neurocrine Biosciences | 73 | 2024-03-20 | 2026-07-17 |
Showing 20 of 417. Sign in to see all of them.
Depressive Disorder, Major (326) · Depression (170) · Depressive Disorder, Treatment-Resistant (42) · Mood Disorders (28) · Depression, Postpartum (22) · Bipolar Disorder (19) · Anxiety Disorders (16) · Mental Disorders (15) · Dysthymic Disorder (13) · Anhedonia (7) · Alcoholism (6) · Psychotic Disorders (6) · Behavioral Symptoms (5) · Cognitive Dysfunction (5)
Mental Disorders (402) · Mood Disorders (389) · Behavior (177) · Behavioral Symptoms (168) · Pathological Conditions, Signs and Symptoms (31) · Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (23) · Nervous System Diseases (23) · Pregnancy Complications (20) · Signs and Symptoms (20) · Bipolar and Related Disorders (19) · Puerperal Disorders (19) · Neurologic Manifestations (16) · Pathologic Processes (14)
Ketamine (22) · Escitalopram (19) · Psilocybin (14) · Sertraline (13) · Venlafaxine Hydrochloride (12) · Transcranial Direct Current Stimulation (11) · Citalopram (10) · Cognitive Behavioral Therapy (10) · Fluoxetine (10) · Therapeutics (9) · Bupropion (8) · Vortioxetine (8) · Paroxetine (7) · Transcranial Magnetic Stimulation (7) · Duloxetine Hydrochloride (5)
GlaxoSmithKline (14) · National Institute of Mental Health (NIMH) (13) · Janssen Research & Development, LLC (12) · Massachusetts General Hospital (10) · New York State Psychiatric Institute (8) · University of Pittsburgh (8) · H. Lundbeck A/S (7) · Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · Alto Neuroscience (6) · The University of New South Wales (6) · Icahn School of Medicine at Mount Sinai (5) · Sanofi (5) · Shanghai Mental Health Center (5) · University of Sao Paulo (5) · AstraZeneca (4)
United States (266) · Canada (36) · Germany (31) · Russia (21) · Australia (20) · Poland (20) · United Kingdom (19) · Japan (16) · Bulgaria (15) · China (15) · Finland (12) · Ukraine (12) · Spain (11) · Sweden (11) · Belgium (10)
Maurizio Fava, MD (6) · Carlos A Zarate, M.D. (4) · Andre R Brunoni, MD (3) · Andrew A Nierenberg, MD (2) · Colleen Loo (2)
PMID 34510411, PMID 23146246, PMID 27685842, PMID 28086004, PMID 30508090, PMID 31270774, PMID 33128208, PMID 34817851, PMID 35092868, PMID 37585253, PMID 39955416, PMID 40398609, PMID 42304135, PMID 42521762, PMID 10197825, PMID 12113998, PMID 12217271, PMID 14557145, PMID 15365580, PMID 15580167, PMID 15583115, PMID 15982444, PMID 16319710, PMID 16390366, PMID 16491981, PMID 16894061, PMID 17215046, PMID 17690799, PMID 18061147, PMID 18295436, PMID 18314433, PMID 18457236, PMID 18480694, PMID 18996507, PMID 19182688, PMID 19192466, PMID 19223438, PMID 19321268, PMID 19414708, PMID 19485586, PMID 19730273, PMID 19730274, PMID 19744406, PMID 19858762, PMID 19968380, PMID 20008943, PMID 20351570, PMID 20478877, PMID 20576364, PMID 20592433
2015 (4), 2016 (3), 2019 (3), 2008 (2), 2023 (2), R33MH122464 (2), 2009 (1), 2014 (1), 2017 (1), 2018 (1), 271201100006I-0-27100007-1 (1), K23MH064528 (1), K23MH066265 (1), K24AT004095 (1), KL2RR024154 (1)